$22.530
+0.532 (+2.36%)At close
AMPH News
AMPH Events
Company Reports Q2 Revenue of $183.9M, Exceeding Expectations
Reports Q2 revenue $183.9M, consensus $179.92M. "Our Q2 results reflect the continued execution of our long-term strategy to build a more diversified and innovative biopharmaceutical company. While we continued to navigate pricing and competitive dynamics across portions of our portfolio, we successfully achieved key goals including overall revenue growth, expansion of gross margins, meaningful launches of new products, and continued advancement from both our generic and proprietary development pipelines. These results demonstrate the strength of our integrated business model and position us well for long-term sustainable growth," said CEO Jack Zhang.
Amphastar Reports Q1 Revenue of $171.2M
Yesterday evening, the company also reported Q1 revenue $171.2M, consensus $173.4M. "In the first quarter of 2026, we continued to strengthen our commercial foundation and core business, highlighted by the approval and subsequent launch of Ipratropium Bromide HFA, while also making meaningful advancements across our pipeline that will support our long-term strategy," said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer. "To begin the year, we broadened our portfolio through an exclusive license agreement for a fully synthetic corticotropin compound. At the same time, we remain committed to investing in our proprietary pipeline and capabilities, which we believe will support sustainable long-term growth."
Q4 Revenue at $183.11M, Below Consensus of $190.48M
Reports Q4 revenue $183.11M, consensus $190.48M.
Amphastar Receives FDA Approval for Ipratropium Bromide Inhalation Aerosol
Amphastar announced that the FDA has approved the company's abbreviated new drug application, or ANDA, for Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation. The FDA determined that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is bioequivalent and therapeutically equivalent to Boehringer Ingelheim's Atrovent HFA Inhalation Aerosol. Additionally, the FDA has confirmed that this product is eligible for 180-days of generic drug exclusivity for Ipratropium Bromide HFA Inhalation Aerosol as we were the first ANDA applicant with Paragraph IV certification. This exclusivity period will begin on the first day that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is commercially launched.
Amphastar Pharmaceuticals Receives FDA Approval for Teriparatide Injection
Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the Company's Abbreviated New Drug Application for teriparatide injection, USP 560 mcg/2.24mL single-patient-use prefilled pen. The FDA determined that Amphastar's teriparatide is bioequivalent and therapeutically equivalent to Eli Lilly's FORTEO.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.